RESUMO
Abstract Background: Cardiac cachexia is an important predictive factor of the reduction in survival of patients with heart failure with reduced ejection fraction. Objectives: The aims of the present study were to evaluate adropin and irisin levels in cachectic and non-cachectic subjects and the relationships between the levels of these proteins and clinical and laboratory parameters in patients with HFrEF. Methods: The clinical records of patients who were admitted to the cardiology outpatient clinic for heart failure with reduced ejection fraction were screened. Cachectic patients were identified and assigned to the study group (n = 44, mean age, 65.4 ± 11.2 y; 61.4% men). Heart failure with reduced ejection fraction patients without weight loss were enrolled as the control group (n = 42, mean age, 61.0 ± 16.5 y; 64.3% men). The serum adropin and irisin levels of all patients were measured. A p-value < 0.05 was considered significant. Results: Serum adropin and irisin levels were significantly higher in the cachexia group than in the controls (Adropin (ng/L); 286.1 (231.3-404.0) vs 213.7 (203.1-251.3); p < 0.001, Irisin (µg/mL); 2.6 (2.2-4.4) vs 2.1 (1.8-2.4); p = 0.001). Serum adropin and irisin levels were positively correlated with brain natriuretic peptide (BNP) levels and New York Heart Association (NYHA) class and negatively correlated with body mass index (BMI) and serum albumin levels (all p values: < 0.001). In a multivariate analysis, adropin was the only independent predictor of cachexia in the heart failure with reduced ejection fraction patients (OR: 1.021; 95% CI: 1.004−1.038; p = 0.017). Conclusions: The results suggest that adropin and irisin may be novel markers of cardiac cachexia in heart failure with reduced ejection fraction patients. Adropin and irisin are related with the severity of heart failure.
Resumo Fundamento: A caquexia cardíaca é um importante preditor de redução de sobrevida em pacientes com insuficiência cardíaca com fração de ejeção reduzida (ICFER). O objetivo deste estudo foi avaliar os níveis de adropina e irisina em pacientes com ICFER caquéticos e não caquéticos, assim como a relação entre os níveis dessas proteínas e os parâmetros clínicos e laboratoriais nesses pacientes. Objetivos: Os objetivos do presente estudo foram avaliar os níveis de adropina e irisina em indivíduos caquéticos e não caquéticos e as relações entre os níveis dessas proteínas e os parâmetros clínicos e laboratoriais em pacientes com ICFEN. Métodos: Os prontuários de pacientes atendidos no ambulatório de cardiologia para ICFER foram triados. Aqueles com ICFER caquéticos foram identificados e constituíram o grupo de estudo (n = 44; idade média, 65,4 ± 11,2 anos; 61,4% de homens). Aqueles com ICFER e sem perda de peso foram arrolados como grupo controle (n = 42; idade média, 61,0 ± 16,5 anos; 64,3% de homens). Os níveis séricos de adropina e irisina de todos os pacientes foram medidos. Considerou-se significativo um p-valor < 0,05. Resultados: Os níveis séricos de adropina e irisina foram significativamente mais altos nos pacientes caquéticos do que nos controles [adropina (ng/l): 286,1 (231,3-404,0) vs 213,7 (203,1-251,3); p < 0,001; irisina (µg/ml): 2,6 (2,2-4,4) vs 2,1 (1,8-2,4); p = 0,001]. Os níveis séricos de adropina e irisina correlacionaram-se positivamente com os níveis de peptídeo natriurético cerebral (BNP) e a classe funcional da New York Heart Association (NYHA), e negativamente com o índice de massa corporal (IMC) e os níveis séricos de albumina (todos os p-valores: < 0,001). Na análise multivariada, a adropina foi o único preditor independente de caquexia nos pacientes com ICFER (OR: 1,021; IC 95%: 1,004−1,038; p = 0,017). Conclusões: Os resultados sugerem que a adropina e a irisina possam ser novos marcadores de caquexia cardíaca em pacientes com ICFER. Adropina e irisina estão relacionadas com a gravidade da insuficiência cardíaca.
Assuntos
Humanos , Feminino , Pessoa de Meia-Idade , Idoso , Peptídeos/sangue , Caquexia/sangue , Fibronectinas/sangue , Disfunção Ventricular Esquerda/sangue , Insuficiência Cardíaca/sangue , Caquexia/etiologia , Proteínas Sanguíneas , Biomarcadores/sangue , Estudos de Casos e Controles , Disfunção Ventricular Esquerda/complicações , Peptídeos e Proteínas de Sinalização Intercelular , Insuficiência Cardíaca/complicaçõesRESUMO
Objective Our aim was to investigate the thyroid function tests and thyroid volume differences among males with isolated hypogonadotropic hypogonadism (IHH) who take androgen replacement treatment (ART). Materials and methods Forty-four male with IHH with a mean age 33.2 (18-54), diagnosed in Endocrinology and Metabolism Department between September 2013 and September 2014 and 40 healthy male control with a mean age 27.77 (18-55) were involved to study. Patient group was divided to testosterone-treated patients (n = 19) and human chorionic gonadotropine (hCG)-treated patients (n = 25). Patient group was compared in terms of total testosterone, thyroid function tests [thyroid stimulating hormone (TSH), free thyroxine (fT4)] and thyroid volume, before and 6 months after treatment. Patient group was compared with control group as well. Results When we compared the patient group with the control group, there was no significant difference for age, Body mass index, TSH, fT4 and thyroid volume between two groups before treatment. There was no difference in terms of TSH, but fT4, testosterone levels and thyroid volume were significantly higher after treatment, when the patient group was compared before and after treatment (p < 0.05). When we compared testosterone-treated patients and hCG-treated patients; thyroid volume was higher among hCG-treated patients (p = 0.001) but there was no difference for thyroid volume before and after testosterone treatment (p > 0.05). There was no statistically significant correlation between testosterone levels with TSH, fT4 and thyroid volume (r = 0.09, p = 0.32; r = 0.14, p = 0.11; r = 0.15, p = 0.09, respectively). Conclusion Our study showed that ART increases the thyroid volume especially in hCG-treated patients. Therefore, we suggest that thyroid volume changes should be followed up in hCG-treated patients.
Assuntos
Adulto , Humanos , Masculino , Pessoa de Meia-Idade , Adulto Jovem , Androgênios/uso terapêutico , Gonadotropina Coriônica/uso terapêutico , Terapia de Reposição Hormonal , Hipogonadismo/tratamento farmacológico , Glândula Tireoide/efeitos dos fármacos , Índice de Massa Corporal , Estudos de Casos e Controles , Hipogonadismo/sangue , Tamanho do Órgão/efeitos dos fármacos , Testes de Função Tireóidea , Testosterona/sangue , Testosterona/uso terapêutico , Glândula Tireoide , Tireotropina/sangue , Tiroxina/sangueRESUMO
Aim: Anomalies of aortic arch are uncommon, accounting for only 1-3% of all congenital cardiac diseases. A vascular ring results from the abnormal development of an aortic arch complex. Generally, it manifests with tracheoesophageal compression symptoms during infancy. We aimed to discuss clinical and imaging findings of two cases of vascular ring based on existing literature. Cases: This article presents two cases of a 4-year-old child diagnosed with right sided aortic arch and a new-born child diagnosed with double aortic arch in neonatal unit. The first patient presented with complaints of coughing, wheezing and shortness of breath, the second patient suffered from respiratory distress. In the both cases, diagnosis were established using multi-detector computed tomography (MDCT). Both patients were diagnosed with vascular ring, considering their existing findings, and referred for surgery. Discussion: Apparent airway obstructions lead to critical complaints at early ages. Moderately severe symptoms and the non-existence of anatomic compression may cause resulting diseases to be diagnosed in a later period of life. A vascular ring can be diagnosed using chest radiography, barium oesophagus graphy, transthoracic echocardiography, MDCT, magnetic resonance imaging and angiography. However, pathologies of the studied cases (right aortic arch, double aortic arch, and tracheal compression) are effectively observed with MDCT and using the post-processing images of MDCT. Conclusion: A vascular ring should be considered in the event of recurrent lung infections, unexplained coughs, wheezing and stridor during childhood as well as in the case of unexplained respiratory distress in new-born children. MDCT is an excellent modality for patients suspected of having a vascular ring.